A lack of evidence is behind the NHS' decision to withhold a breakthrough prostate cancer drug from patients who have already been treated using another new generation drug, Nice said.
A spokeswoman for Nice said the committee were unable to "draw any conclusions" about what would happen if "milestone" enzalutamide was used by prostate cancer sufferers who had also taken abiraterone.
In the trial data provided by the manufacturer of enzalutamide none of the patients had received previous treatment with abiraterone, therefore the committee was not able to draw any conclusions about the effectiveness of enzalutamide after previous abiraterone treatment, and this is reflected in the recommendations.
We would welcome any additional data the manufacturer of enzalutamide can provide.
More top news
A hacker group who claimed to be behind a cyber attack on Sony Pictures have posted a message online apparently mocking the FBI.
The returns of Benedict Cumberbatch's detective and the X Factor judge were among 2014's most tweeted TV moments in a billion conversations.
A family has issued an appeal to help find their missing pet turkey - in case he gets gobbled up as someone's Christmas dinner.